Fibroblast growth factor 23 and bone mineralisation

International Journal of Oral Science

Volumn 7, Issue , 2015, Pages 8-13

  Guo, Yu Chen ^a   Yuan, Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

bone mineralisation; chronic kidney disease; fibroblast growth factor 23

Indexed keywords

BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN;

BIOSYNTHESIS; BONE MINERALIZATION; HUMAN; METABOLISM; PHYSIOLOGY;

CALCIFICATION, PHYSIOLOGIC; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS;

EID: 84925441827     PISSN: 16742818     EISSN: 20493169     Source Type: Journal    
DOI: 10.1038/ijos.2015.1     Document Type: Review

References (111)

1. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113(4): 561-568.
2. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23(7): 421-432.
3. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61: 91-104.
4. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26(3): 345-348.
5. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98(11): 6500-6505.
6. Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone 2007; 40(5): 1190-1195.
7. Garringer HJ, Fisher C, Larsson TE et al. The role of mutant UDP-N-acetyl-alpha-Dgalactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 2006; 91(10): 4037-4042.
8. Khosravi A, Cutler CM, Kelly MH et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab 2007; 92(6): 2374-2377.
9. Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89(8): 3979-3982.
10. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314(2): 409-414.
11. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19(3): 429-435.
12. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18(7): 1227-1234.
13. Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol 2013; 5(6):pii:a015958.
14. Coutts JC, Gallagher JT. Receptors for fibroblast growth factors. Immunol Cell Biol 1995; 73(6): 584-589.
15. Ornitz DM, Xu J, Colvin JS et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271(25): 15292-15297.
16. Sleeman M, Fraser J, McDonald M et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001; 271(2): 171-182.
17. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390(6655): 45-51.
18. Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006; 12(7): 298-305.
19. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444(7120): 770-774.
20. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281(10): 6120-6123.
21. Yoshiko Y, Wang H, Minamizaki T et al. Mineralized tissue cells are a principal source of FGF23. Bone 2007; 40(6): 1565-1573.
22. Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35(5): 1192-1199.
23. Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112(5): 683-692.
24. Parfitt AM. The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption-bone flow theory. Clin Orthop Relat Res 1977; (127): 236-247.
25. Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38(11): 1310-1315.
26. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Dmp1-nullmice. Am J Physiol Endocrinol Metab 2008; 295(2): E254-E261.
27. Liu S, Rowe PS, Vierthaler L et al. Phosphorylated acidic serine-aspartate-rich MEPEassociated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007; 192(1): 261-267.
28. Pereira RC, Juppner H, Azucena-Serrano CE et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45(6): 1161-1168.
29. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11(2): 130-136.
30. Thompson DL, Sabbagh Y, Tenenhouse HS et al. Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res 2002; 17(2): 311-320.
31. Nampei A, Hashimoto J, Hayashida K et al. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 2004; 22(3): 176-184.
32. Rowe PS, Oudet CL, Francis F et al. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 1997; 6(4): 539-549.
33. Strom TM, Francis F, Lorenz B et al. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 1997; 6(2): 165-171.
34. Gowen LC, Petersen DN, Mansolf AL et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003; 278(3): 1998-2007.
35. Martin A, Liu S, David V et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011; 25(8): 2551-2562.
36. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291(1): E38-E49.
37. Woo SM, Rosser J, Dusevich V et al. Cell line IDG-SW3 replicates osteoblast-to-lateosteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res 2011; 26(11): 2634-2646.
38. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299(4): F882-F889.
39. Stubbs JR, He N, Idiculla A et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012; 27(1): 38-46.
40. Huang XL, Jiang Y, Xia WB. FGF23 and Phosphate Wasting Disorders. Bone Res 2013; 1(2): 120-132.
41. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26(3): 345-348.
42. Nelson AE, Hogan JJ, Holm IA et al. Phosphate wasting in oncogenic osteomalacia: PHEX is normal and the tumor-derived factor has unique properties. Bone 2001; 28(4): 430-439.
43. Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012; 318(9): 1040-1048.
44. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012; 30(1): 1-9.
45. Chong WH, Molinolo AA, Chen CC et al. Tumor-induced osteomalacia. Endocr Relat Cancer 2011; 18(3): R53-R77.
46. Owen C, Chen F, Flenniken AM et al. A novel Phex mutation in a new mouse model of hypophosphatemic rickets. J Cell Biochem 2012; 113(7): 2432-2441.
47. Khaliq W, Cheripalli P, Tangella K. Tumor-induced osteomalacia (TIO): atypical presentation. South Med J 2011; 104(5): 348-350.
48. van der Rest C, Cavalier E, Kaux JF et al. Tumor-induced osteomalacia: the tumor may stay hidden! Clin Biochem 2011; 44(14/15): 1264-1266.
49. Larsson T, Yu X, Davis SI et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005; 90(4): 2424-2427.
50. Wang H, Yoshiko Y, Yamamoto R et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008; 23(6): 939-948.
51. Sitara D, Kim S, Razzaque MS et al. Genetic evidence of serum phosphateindependent functions of FGF-23 on bone. PLoS Genet 2008; 4(8): e1000154.
52. Shalhoub V, Ward SC, Sun B et al. Fibroblast growth factor 23 (FGF23) and alphaklotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 2011; 89(2): 140-150.
53. Sitara D, Razzaque MS, St-Arnaud R et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006; 169(6): 2161-2170.
54. Razzaque MS, Sitara D, Taguchi T et al. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006; 20(6): 720-722.
55. Yuan Q, Sato T, Densmore M et al. FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J Bone Miner Res 2011; 26(9): 2026-2035.
56. Yuan Q, Sitara D, Sato T et al. PTH ablation ameliorates the anomalies of Fgf23-deficient mice by suppressing the elevated vitamin D and calcium levels. Endocrinology 2011; 152(11): 4053-4061.
57. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11(3): 279-303.
58. Yuan Q, Jiang Y, Zhao X et al. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice. J Bone Miner Res 2014; 29(3): 693-704.
59. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444(7120): 770-774.
60. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281(10): 6120-6123.
61. Tomiyama K, Maeda R, Urakawa I et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A 2010; 107(4): 1666-1671.
62. Rhee Y, Bivi N, Farrow E et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011; 49(4): 636-643.
63. -/- mice. PLoS Genet 2012; 8(5): e1002726.
64. Nakatani T, Sarraj B, Ohnishi M et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009; 23(2): 433-441.
65. Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317(5839): 803-806.
66. Brownstein CA, Zhang J, Stillman A et al. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology 2010; 151(2): 492-501.
67. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16(7): 2205-2215.
68. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64(6): 2272-2279.
69. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44(2): 250-256.
70. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010; 77(4): 292-298.
71. Gutiérrez OM. Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy. J Ren Nutr 2013; 23(3): 250-254.
72. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71(1): 31-38.
73. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90(3): 1519-1524.
74. Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21(8): 1187-1196.
75. Nishida Y, Taketani Y, Yamanaka-Okumura H et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006; 70(12): 2141-2147.
76. Ito N, Fukumoto S, Takeuchi Y et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 2007; 25(6): 419-422.
77. Urena Torres P, Friedlander G, de Vernejoul MC et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 2008; 73(1): 102-107.
78. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006; 70(8): 1486-1494.
79. Evenepoel P, Naesens M, Claes K et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7(5): 1193-1200.
80. Koh N, Fujimori T, Nishiguchi S et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001; 280(4): 1015-1020.
81. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359(6): 584-592.
82. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24(9): 2792-2796.
83. Olauson H, Qureshi AR, Miyamoto T et al. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant 2010; 25(9): 3033-3038.
84. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant 2005; 20(7): 1295-1298.
85. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67(3): 1120-1125.
86. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67(3): 1171-1178.
87. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101(2): c94-c99.
88. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011; 79(1): 112-119.
89. Hansen D, Rasmussen K, Pedersen SM et al. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2012; 27(6): 2263-2269.
90. Wetmore JB, Liu S, Krebill R et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5(1): 110-116.
91. Koizumi M, Komaba H, Nakanishi S et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012; 27(2): 784-790.
92. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9(4): 336-339.
93. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44(3): 481-487.
94. Shigematsu T, Negi S, COLC Research Group. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant 2012; 27(3): 1050-1054.
95. Takeda Y, Komaba H, Goto S et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011; 33(5): 421-426.
96. López I, Rodríguez-Ortiz ME, Almadén Y et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 80(5): 475-482.
97. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17(5): 1305-1315.
98. Jüppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010; 25(10): 2091-2097.
99. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22(5): 956-966.
100. Kalantar-Zadeh K, Kopple JD, Humphreys MH et al. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004; 19(6): 1507-1519.
101. Stenvinkel P, Lindholm B, Heimbürger M et al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15(10): 1624-1630.
102. Dai B, David V, Martin A et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE 2012; 7(9): e44161.
103. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121(11): 4393-4408.
104. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73(12): 1355-1363.
105. Melamed ML, Michos ED, Post W et al. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15): 1629-1637.
106. Mehrotra R, Kermah DA, Salusky IB et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76(9): 977-983.
107. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72(8): 1004-1013.
108. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94(2): 511-517.
109. Lu Y, Ye L, Yu S et al. Rescue of odontogenesis in Dmp1-deficient mice by targeted reexpression of DMP1 reveals roles for DMP1 in early odontogenesis and dentin apposition in vivo. Dev Biol 2007; 303(1): 191-201.
110. Lu Y, Liu S, Xie Y et al. Use of the transgenic approach to determine the role of DMP1 in phosphate regulation. J Musculoskelet Neuronal Interact 2007; 7(4): 309.
111. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122(7): 2543-2553.